From Repurposing to Refinement: Optimizing Levofloxacin for Treatment of Multidrug-Resistant Tuberculosis
- PMID: 40315145
- PMCID: PMC12264645
- DOI: 10.1164/rccm.202503-0550ED
From Repurposing to Refinement: Optimizing Levofloxacin for Treatment of Multidrug-Resistant Tuberculosis
Comment on
-
Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial.Am J Respir Crit Care Med. 2025 Jul;211(7):1277-1287. doi: 10.1164/rccm.202407-1354OC. Am J Respir Crit Care Med. 2025. PMID: 40080768 Free PMC article. Clinical Trial.
References
-
- Yoon YS, Lee HJ, Yoon HI, Yoo CG, Kim YW, Han SK. et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis . 2005;9:1215–1219. - PubMed
-
- Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M. et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med . 2004;169:1103–1109. - PubMed
-
- Ahmad N, Ahuja SD, Akkerman OW, Alffenaar J-WC, Anderson LF, Baghaei P. et al. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTB. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet . 2018;392:821–834. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
